Linked Life Data

20132413

Source:http://linkedlifedata.com/resource/pubmed/id/20132413

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-5-6
pubmed:abstractText
Ovarian/primary peritoneal carcinoma and breast carcinoma are the gynaecological cancers that most frequently involve the serosal cavities.With the objective of improving on the limited diagnostic panel currently available for the differential diagnosis of these two malignancies,as well as to define tumour-specific biological targets, we compared their global gene expression patterns. Gene expression profiles of 10 serous ovarian/peritoneal and eight ductal breast carcinoma effusions were analysed using the HumanRef-8 BeadChip from Illumina.Differentially expressed candidate genes were validated using quantitative real-time PCR and immunohistochemistry. Unsupervised hierarchical clustering using all 54,675 genes in the array separated ovarian from breast carcinoma samples. We identified 288 unique probes that were significantly differentially expressed in the two cancers by greater than 3.5-fold, of which 81 and 207 were overexpressed in breast and ovarian/peritoneal carcinoma, respectively. SAM analysis identified 1078 differentially expressed probes with false discovery rate less than 0.05. Genes overexpressed in breast carcinoma included TFF1, TFF3, FOXA1, CA12, GATA3, SDC1, PITX1, TH, EHFD1, EFEMP1, TOB1 and KLF2. Genes overexpressed in ovarian/peritoneal carcinoma included SPON1, RBP1, MFGE8, TM4SF12, MMP7, KLK5/6/7, FOLR1/3,PAX8, APOL2 and NRCAM. The differential expression of 14 genes was validated by quantitative real-time PCR, and differences in 5 gene products were confirmed by immunohistochemistry. Expression profiling distinguishes ovarian/peritoneal carcinoma from breast carcinoma and identifies genes that are differentially expressed in these two tumour types. The molecular signatures unique to these cancers may facilitate their differential diagnosis and may provide a molecular basis for therapeutic target discovery.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1582-4934
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
535-44
pubmed:meshHeading
pubmed-meshheading:20132413-Adult, pubmed-meshheading:20132413-Aged, pubmed-meshheading:20132413-Breast Neoplasms, pubmed-meshheading:20132413-Carbonic Anhydrases, pubmed-meshheading:20132413-Cluster Analysis, pubmed-meshheading:20132413-Cystadenocarcinoma, Serous, pubmed-meshheading:20132413-Diagnosis, Differential, pubmed-meshheading:20132413-Female, pubmed-meshheading:20132413-Gene Expression Profiling, pubmed-meshheading:20132413-Gene Expression Regulation, Neoplastic, pubmed-meshheading:20132413-Hepatocyte Nuclear Factor 3-alpha, pubmed-meshheading:20132413-Humans, pubmed-meshheading:20132413-Immunohistochemistry, pubmed-meshheading:20132413-Matrix Metalloproteinase 7, pubmed-meshheading:20132413-Middle Aged, pubmed-meshheading:20132413-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:20132413-Ovarian Neoplasms, pubmed-meshheading:20132413-Peptides, pubmed-meshheading:20132413-Peritoneal Neoplasms, pubmed-meshheading:20132413-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20132413-Tumor Suppressor Proteins
pubmed:year
2011
pubmed:articleTitle
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
pubmed:affiliation
Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. bend@medisin.uio.no
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural